Standard type 1 diabetes management model constructed by China Alliance for Type 1 Diabetes in each center
OtherStandard type 1 diabetes management model constructed by China Alliance for Type 1 Diabetes in each center
NCT Number: NCT05498974
The aim of the China Diabetes Type 1 Study (CD1S) is to conduct a nationwide type 1 diabetes (T1D) registry study in patients with T1D and in pediatric adolescent patients with diabetes who had an age of onset <= 20 years.
CD1S compromises a retrospective study enrolling inpatients hospitalized from Jan 1st, 2016 to Dec 31, 2021, and a prospective study beginning from the year 2022.
Interested in participating?
Request InfoAll sexes
Observational
Gansu Provincial People's Hospital, Lanzhou, Gansu, China
The aim of the China Diabetes Type 1 Study (CD1S) is to conduct a nationwide type 1 diabetes (T1D) registry study to investigate the demographic characteristics, metabolic control, complications occurrence as well as risk factors of patients with T1D, and to investigate the clinical features, complications' burdens and risk factors in pediatric adolescent patients with diabetes who had an age of onset <= 20 years.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Standard type 1 diabetes management model constructed by China Alliance for Type 1 Diabetes in each center
Time frame: Every year for up to 10 years
A1c reflects the average blood glucose level
Time frame: up to 10 years
Albumin-to-creatinine ratio in urine sample
Time frame: up to 10 years
Incident cases of cardiovascular diseases
Time frame: up to 10 years
value of nerve conduction velocity, F wave index, H-reflex
Time frame: up to 10 years
PHQ-9(a score between 0-27, ≥10 may indicate depression)
Time frame: up to 10 years
GAD-7(a score between 0-21, ≥5 may indicate general anxiety)
Time frame: up to 10 years
WHO-5 (a score between 0-100, higher score means better outcome)
Time frame: up to 10 years
PAID (a score between 0-100, ≥40 warrants special attention).
Time frame: Every year for up to 10 years
C-peptide are measured before and 2-hour after a mixed meal tolerance test at each follow-up of this study
Time frame: Every year for up to 10 years
Glutamic acid decarboxylase antibody using radioligand binding assay method
Time frame: Every year for up to 10 years
the blood sugar level after fasting for eight hours
Time frame: Every year for up to 10 years
Systolic blood pressure
Time frame: Every year for up to 10 years
Diastolic blood pressure
Time frame: Every year for up to 10 years
Including triglyceride, total cholesterol, HDL-cholesterol and LDL-cholesterol
Time frame: Every year for up to 10 years
un-targeted metabolomics using the LC-MS/MS system
Contact information is provided by the study sponsor or research team.
Xia Li, MD, PhD
CONTACT
Zhiguang Zhou, MD, PhD
CONTACT
Second Xiangya Hospital of Central South University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04074668
Autoimmune Diabetes, Autoimmune Diseases
Aurora, Colorado, United States
View Trial DetailsNCT04956263
Autoimmune Diseases, Diabetes
Chula Vista, California, United States
View Trial DetailsNCT03648918
Autoimmune Diseases, Diabetes Mellitus
Milwaukee, Wisconsin, United States
View Trial DetailsNCT06753994
Behavior, Diabetes
Montreal, Quebec, Canada
View Trial Details